Arizona State Retirement System grew its position in Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) by 4.7% in the first quarter, Holdings Channel.com reports. The fund owned 18,508 shares of the biotechnology company's stock after buying an additional 832 shares during the period. Arizona State Retirement System's holdings in Axon Enterprise were worth $2,549,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors have also made changes to their positions in the company. Vaughan Nelson Investment Management L.P. bought a new stake in shares of Axon Enterprise in the 1st quarter valued at approximately $12,825,000. State of New Jersey Common Pension Fund D grew its stake in Axon Enterprise by 6.8% during the 1st quarter. State of New Jersey Common Pension Fund D now owns 40,534 shares of the biotechnology company's stock worth $5,583,000 after buying an additional 2,567 shares during the last quarter. Securian Asset Management Inc. grew its stake in Axon Enterprise by 3.7% during the 1st quarter. Securian Asset Management Inc. now owns 6,144 shares of the biotechnology company's stock worth $846,000 after buying an additional 220 shares during the last quarter. Calamos Advisors LLC grew its stake in Axon Enterprise by 17.6% during the 1st quarter. Calamos Advisors LLC now owns 23,963 shares of the biotechnology company's stock worth $3,300,000 after buying an additional 3,594 shares during the last quarter. Finally, Mutual of America Capital Management LLC grew its stake in Axon Enterprise by 5.9% during the 1st quarter. Mutual of America Capital Management LLC now owns 65,417 shares of the biotechnology company's stock worth $9,010,000 after buying an additional 3,648 shares during the last quarter. 72.06% of the stock is currently owned by institutional investors.
Get Axon Enterprise alerts:Axon Enterprise Stock Up 2.1 %
Shares of Axon Enterprise stock opened at $110.19 on Friday. The stock has a 50-day moving average price of $95.39 and a 200 day moving average price of $113.99. The company has a market cap of $7.82 billion, a P/E ratio of 211.91 and a beta of 0.61. The company has a current ratio of 2.43, a quick ratio of 2.18 and a debt-to-equity ratio of 0.02. Axon Enterprise, Inc. has a 1 year low of $82.49 and a 1 year high of $209.00.
Axon Enterprise (NASDAQ:AXON – Get Rating) last issued its earnings results on Tuesday, May 10th. The biotechnology company reported $0.76 earnings per share for the quarter. Axon Enterprise had a return on equity of 3.90% and a net margin of 4.62%. The company had revenue of $256.43 million for the quarter, compared to analyst estimates of $233.57 million. During the same period in the prior year, the firm posted ($0.75) EPS. The business's revenue was up 31.5% compared to the same quarter last year. As a group, analysts expect that Axon Enterprise, Inc. will post 1.35 EPS for the current fiscal year.Insiders Place Their Bets
In other news, Director Mark W. Kroll sold 3,159 shares of the stock in a transaction dated Wednesday, June 8th. The stock was sold at an average price of $102.82, for a total transaction of $324,808.38. Following the transaction, the director now owns 13,691 shares of the company's stock, valued at approximately $1,407,708.62. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 6.90% of the company's stock.
Analysts Set New Price Targets
AXON has been the subject of a number of recent research reports. Northland Securities lowered their price objective on Axon Enterprise from $180.00 to $130.00 in a research note on Thursday, May 12th. Morgan Stanley cut Axon Enterprise from an "overweight" rating to an "equal weight" rating and set a $120.00 price target for the company. in a research note on Monday, May 23rd. JMP Securities reissued a "buy" rating and issued a $195.00 price target on shares of Axon Enterprise in a research note on Wednesday, June 1st. Robert W. Baird decreased their price target on Axon Enterprise from $145.00 to $125.00 in a research note on Wednesday, May 11th. Finally, Credit Suisse Group decreased their price target on Axon Enterprise from $169.00 to $134.00 in a research note on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $169.00.
About Axon Enterprise
(Get Rating)
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, TASER, and Software and Sensors. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
See Also
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- Procter's Earnings Start To Show Weakness In Q4
- MarketBeat: Week in Review 7/25 – 7/29
- The One Question You Have to Ask Before Investing in INTC Stock
- Home Depot: A Beautiful Boring Stock to Navigate a Bear Market
- Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.
